The Ten Most Common Questions on Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Patients
Abstract With the rising number of patients undergoing hematopoietic stem cell transplantation (HSCT), clinicians are more likely to encounter infectious complications in immunocompromised hosts, particularly cytomegalovirus (CMV) infection. Besides the high mortality of CMV end-organ disease, patie...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAABRON PRESS
2022-12-01
|
| Series: | Clinical Hematology International |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s44228-022-00025-3 |
| _version_ | 1827299145839280128 |
|---|---|
| author | Johnny Zakhour Fatima Allaw Sara F. Haddad Souha S. Kanj |
| author_facet | Johnny Zakhour Fatima Allaw Sara F. Haddad Souha S. Kanj |
| author_sort | Johnny Zakhour |
| collection | DOAJ |
| description | Abstract With the rising number of patients undergoing hematopoietic stem cell transplantation (HSCT), clinicians are more likely to encounter infectious complications in immunocompromised hosts, particularly cytomegalovirus (CMV) infection. Besides the high mortality of CMV end-organ disease, patients with detectable CMV viremia may have worse outcomes and decreased survival even in the absence of end-organ disease. In view of the implications on morbidity and mortality, clinicians should maintain a high index of suspicion and initiate antiviral drugs promptly when CMV infection is confirmed. High-risk patients should be identified in order to provide optimal management. Additionally, novel antiviral agents with a good safety profile and minor adverse events are now available for prophylaxis in high-risk patients and for treatment of resistant or refractory CMV infection. The following review provides concise, yet comprehensive, guidance on the burden and risk factors of CMV in this population, as well as an update on the latest evidence for the management of CMV infection. |
| first_indexed | 2024-04-24T15:27:56Z |
| format | Article |
| id | doaj.art-9c4092d38e3d4f64a4d77e8ff719f22b |
| institution | Directory Open Access Journal |
| issn | 2590-0048 |
| language | English |
| last_indexed | 2024-04-24T15:27:56Z |
| publishDate | 2022-12-01 |
| publisher | SAABRON PRESS |
| record_format | Article |
| series | Clinical Hematology International |
| spelling | doaj.art-9c4092d38e3d4f64a4d77e8ff719f22b2024-04-02T05:33:45ZengSAABRON PRESSClinical Hematology International2590-00482022-12-0151212810.1007/s44228-022-00025-3The Ten Most Common Questions on Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant PatientsJohnny Zakhour0Fatima Allaw1Sara F. Haddad2Souha S. Kanj3Internal Medicine Department, Infectious Diseases Division, Center of Infectious Disease Research, American University of Beirut Medical CenterInternal Medicine Department, Infectious Diseases Division, Center of Infectious Disease Research, American University of Beirut Medical CenterInternal Medicine Department, Infectious Diseases Division, Center of Infectious Disease Research, American University of Beirut Medical CenterInternal Medicine Department, Infectious Diseases Division, Center of Infectious Disease Research, American University of Beirut Medical CenterAbstract With the rising number of patients undergoing hematopoietic stem cell transplantation (HSCT), clinicians are more likely to encounter infectious complications in immunocompromised hosts, particularly cytomegalovirus (CMV) infection. Besides the high mortality of CMV end-organ disease, patients with detectable CMV viremia may have worse outcomes and decreased survival even in the absence of end-organ disease. In view of the implications on morbidity and mortality, clinicians should maintain a high index of suspicion and initiate antiviral drugs promptly when CMV infection is confirmed. High-risk patients should be identified in order to provide optimal management. Additionally, novel antiviral agents with a good safety profile and minor adverse events are now available for prophylaxis in high-risk patients and for treatment of resistant or refractory CMV infection. The following review provides concise, yet comprehensive, guidance on the burden and risk factors of CMV in this population, as well as an update on the latest evidence for the management of CMV infection.https://doi.org/10.1007/s44228-022-00025-3Hematopoietic stem cell transplantationCytomegalovirusPreemptive therapyAntimicrobial resistance |
| spellingShingle | Johnny Zakhour Fatima Allaw Sara F. Haddad Souha S. Kanj The Ten Most Common Questions on Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Patients Clinical Hematology International Hematopoietic stem cell transplantation Cytomegalovirus Preemptive therapy Antimicrobial resistance |
| title | The Ten Most Common Questions on Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Patients |
| title_full | The Ten Most Common Questions on Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Patients |
| title_fullStr | The Ten Most Common Questions on Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Patients |
| title_full_unstemmed | The Ten Most Common Questions on Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Patients |
| title_short | The Ten Most Common Questions on Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Patients |
| title_sort | ten most common questions on cytomegalovirus infection in hematopoietic stem cell transplant patients |
| topic | Hematopoietic stem cell transplantation Cytomegalovirus Preemptive therapy Antimicrobial resistance |
| url | https://doi.org/10.1007/s44228-022-00025-3 |
| work_keys_str_mv | AT johnnyzakhour thetenmostcommonquestionsoncytomegalovirusinfectioninhematopoieticstemcelltransplantpatients AT fatimaallaw thetenmostcommonquestionsoncytomegalovirusinfectioninhematopoieticstemcelltransplantpatients AT sarafhaddad thetenmostcommonquestionsoncytomegalovirusinfectioninhematopoieticstemcelltransplantpatients AT souhaskanj thetenmostcommonquestionsoncytomegalovirusinfectioninhematopoieticstemcelltransplantpatients AT johnnyzakhour tenmostcommonquestionsoncytomegalovirusinfectioninhematopoieticstemcelltransplantpatients AT fatimaallaw tenmostcommonquestionsoncytomegalovirusinfectioninhematopoieticstemcelltransplantpatients AT sarafhaddad tenmostcommonquestionsoncytomegalovirusinfectioninhematopoieticstemcelltransplantpatients AT souhaskanj tenmostcommonquestionsoncytomegalovirusinfectioninhematopoieticstemcelltransplantpatients |